Efficacy of adjunctive use of Verapamil with two doses 120 and 240 mg on control of seizure in patients with refractory temporal lobe epilepsy

Shiraz University of Medical Science0 个研究点目标入组 20 人开始时间: 待定最近更新: 2018年2月22日

适应症

试验速览

暂无简介。

•- Male/female patients, aged 18 and above.
•- Diagnosis of epilepsy made on the basis of clinical and EEG findings.
•- Refractory epilepsy is defined as failure of two or more AEDs at maximal tolerated doses and 2 or more seizures per month.
•- There have been no more than 4 weeks between seizures over the 2 months prior to entry to the study.
•- Having stable medication regimen for 8 weeks prior to entry.
•- Patient is male or a non-pregnant female adequately protected from conception.
•- Informed consent by patients or their families/care givers.
•Exclusion criteria:
•- Patient has a progressive neurological condition.
•- Patient has a history of non-compliance for seizure diary completion or frequent clinic visits.
•- Patient is pregnant at the time of enrolment.
•- Patient has any serious medical illness or major psychiatric disorder, history of psudoseizure, or history of suicidal attempt in the past 5 years.
•- Patient has any contraindication for verapamil administration including:
•severe GI narrowing, heart failure, hypertrophic cardiomyopathy, cardiac conduction disturbances, hypotension, hepatic impairment, renal impairment, and known history of hypersensitivity to verapamil.

发起方

Shiraz University of Medical Science